| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 108.00K | 77.00K | 306.00K | 268.00K | 82.00K | 25.00K |
| Gross Profit | -226.00K | -5.00K | 96.00K | 75.00K | 45.00K | 14.00K |
| EBITDA | -31.85M | -32.04M | -35.29M | -42.91M | -33.60M | -17.11M |
| Net Income | -32.73M | -32.90M | -36.24M | -44.25M | -36.23M | -21.61M |
Balance Sheet | ||||||
| Total Assets | 111.83M | 72.58M | 95.44M | 116.33M | 147.03M | 14.80M |
| Cash, Cash Equivalents and Short-Term Investments | 40.16M | 46.24M | 49.08M | 82.70M | 105.11M | 13.53M |
| Total Debt | 351.00K | 840.00K | 1.86M | 2.31M | 128.00K | 8.67M |
| Total Liabilities | 23.60M | 24.77M | 25.28M | 17.39M | 8.46M | 140.37M |
| Stockholders Equity | 88.23M | 47.80M | 70.16M | 98.94M | 138.56M | -125.57M |
Cash Flow | ||||||
| Free Cash Flow | -26.95M | -14.24M | -27.32M | -35.40M | -32.94M | -17.02M |
| Operating Cash Flow | -26.28M | -14.19M | -27.19M | -34.61M | -31.64M | -16.87M |
| Investing Cash Flow | -27.28M | 11.74M | 438.00K | 5.55M | -82.56M | -149.00K |
| Financing Cash Flow | 53.91M | 2.61M | 752.00K | 5.00K | 159.59M | 9.16M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $215.58M | ― | -27.01% | ― | 123.15% | 8.21% | |
55 Neutral | $244.83M | -1.65 | -101.41% | ― | -47.56% | -65.54% | |
52 Neutral | $86.58M | ― | -22.66% | ― | 5.33% | 75.52% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $127.89M | ― | -44.24% | ― | 0.93% | 13.99% | |
43 Neutral | $50.28M | -1.74 | ― | ― | 35.10% | 39.15% | |
41 Neutral | $52.96M | ― | -219.68% | ― | 25.70% | 39.25% |
On September 5, 2025, Sera Prognostics presented a new investor presentation at the H.C. Wainwright 27th Annual Global Investment Conference. The company highlighted its strategic focus on commercializing the PreTRM® test, supported by a strong financial position with $108.5 million in cash and marketable securities. Sera Prognostics aims to address the significant economic burden of preterm births in the U.S., which account for a substantial portion of neonatal healthcare costs. The company is progressing with Medicaid engagement and anticipates a commercial inflection point as it continues to expand its market presence.
The most recent analyst rating on (SERA) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Sera Prognostics stock, see the SERA Stock Forecast page.
Sera Prognostics’ recent earnings call painted a picture of a company making strides in strategic initiatives while grappling with financial hurdles. The sentiment was a mix of optimism and caution, as the company showcased progress in data generation, commercial team expansion, and European market preparation. However, these advancements were overshadowed by a decline in net revenue and persistent net losses, indicating current financial challenges despite the potential for future growth.
Sera Prognostics, Inc., a health diagnostics company based in Salt Lake City, Utah, specializes in precision pregnancy care, offering innovative diagnostic tests to predict preterm birth risks and improve maternal and neonatal health outcomes.